uniQure (QURE) Stock Price, Quote, News & History | Benzinga

uniQure NV (QURE) Stock Price, Quote, News & History

QURENASDAQ

Trade with Public

Trade with Public

$51.05

3.597.56%

At close: Aug 25, 5:00 PM EST

$51.42

0.370.73%

After Hours: 7:36 PM EST

OverviewNews Earnings Forecast Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$48.00

Close

$51.05

Volume / Avg.

2.19M / 1.88M

Day Range

$47.92 - $51.72

52 Wk Range

8.73 - 71.50

Market Cap

$3.57B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

15.61%

Days to Cover

6.79

Recent uniQure N.V. News

Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.

Avi Kapoor

What's Going On With Capricor Therapeutics Stock On Friday?

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy therapy.

Vandana Singh

Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday

Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal with CoreWeave Inc. Other stocks also gained.

Avi Kapoor

uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related serious adverse events.

Vandana Singh

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-160.79M

Investing Cash Flow (TTM)

-262.97M

Financing Cash Flow (TTM)

584.35M

Free Cash Flow (TTM)

-161.45M

Capital Expenditure (TTM)

-665.00K

Net Change in Cash (TTM)

160.59M

Analyst Trends and Forecast

7

5

Mar

1

1

Apr

1

May

5

1

Jun

3

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.80B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

171.00

PB Ratio (TTM)

10.94

Earnings Yield % (TTM)

-7.95%

Earnings Yield % (FWD)

-7.41%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.67

Company Debt

Total Debt

$50.15M

LT Debt

$50.15M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$413.03M

Debt to Equity

0.19

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$48.00

Close

$51.05

Volume / Avg.

2.19M / 1.88M

Day Range

$47.92 - $51.72

52 Wk Range

8.73 - 71.50

Market Cap

$3.57B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

75

Short Interest

15.61%

Days to Cover

6.79

About

Sector

Health Care

Industry

Biotechnology

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy uniQure (QURE) stock?

A

You can purchase shares of uniQure (NASDAQ:QURE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are uniQure (QURE) competitors?

A

Other companies in uniQure’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for uniQure (QURE) stock?

A

uniQure has a consensus price target of $58.40.

Q

What is the current price for uniQure (QURE)?

A

The stock price for uniQure (NASDAQ: QURE) is $51.4225 last updated August 25, 2026 at 7:36 PM EDT.

Q

Does uniQure (QURE) pay a dividend?

A

There are no upcoming dividends for uniQure.

Q

When is uniQure (NASDAQ:QURE) reporting earnings?

A

uniQure does not have any upcoming earnings scheduled.

Q

Is uniQure (QURE) going to split?

A

There is no upcoming split for uniQure.

Q

What sector and industry does uniQure (QURE) operate in?

A

uniQure is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.